Bioperfectus Human Papillomavirus Real Time PCR Kit & Human Papillomavirus Genotyping Real Time PCR Kit are free upgrading to meet different laboratories’ demands.
As latest guidelines released by countries and regions, we can tell that:
1) HPV screening is now encouraged and considered for primary cervical cancer screening in more countries.
2) The routine screening age usually falls between 30-65 years old.
3) The frequency of HPV tests for routine screening is usually encouraged every 5 years.
4) A retest is usually required after the positive result or intervention is followed up, contributing to the total potential test volume.
|
Region
|
Date
|
Guideline
|
Authority*
|
Screening age
|
HPV as primary screening and retest
|
|
Global
|
2021 Jul
|
Guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition
|
WHO
|
30 – 65 yrs old
a regular screening interval of every 5 to 10 yrs when using HPV DNA detection as the primary screening test
|
• Using HPV DNA primary screening test either with triage or without triage
• Retest at 24 months: primary HPV (+) and triage (-)
• Retest at 12 months: treated for histologically confirmed CIN2/3 or AIS or as a result of a positive screening test
|
|
USA
|
2021 Apr
|
Updated Cervical Cancer Screening Guidelines
|
ACOG & ASCCP & SGO & USPSTF
|
• <21 yrs old, no screening
• 21-29 yrs old, cytology alone every 3 yrs
• 30-65 yrs old
- Cytology alone every 3 yrs
- hrHPV test alone (FDA approved) every 5 yrs
- Co-testing (hrHPV + cytology) every 5 yrs
• >65 yrs old, stop after screening result (-)
|
• hrHPV testing alone (FDA approved) every 5 yrs
• Co-testing (hrHPV + cytology) every 5 yrs
|
|
Europe
|
2015 Aug
|
European guidelines for quality assurance
in cervical cancer screening
Second edition - Supplements
|
EC
|
• <30 yrs old, no screening
• >35 yrs old, HPV screening every 5-10 yrs
• >60 or 65 yrs old, stop after screening result (-)
|
• hrHPV primary screening every 5 to 10 yrs
|
|
Saudi Arab
|
2016 Sep
|
Clinical practice
guidelines on the screening and treatment of precancerous lesions for cervical cancer prevention in Saudi Arabia
|
MOH
|
• Within 3 yrs after marriage - 65 yrs old, HPV testing and/or cytology for universal screening
|
• HPV DNA test followed by colposcopy or cytology (Pap test) followed by colposcopy to screen for CIN2+
• HPV testing and/or cytology for universal screening
|
|
Brazil
|
2018 June
|
Guidelines for
HPV‑DNA testing for cervical cancer screening in Brazil
|
ABPTGIC
|
• <30 yrs old, no screening
• 30-65 yrs old, HPV testing or cytology every 5 yrs
• >65 yrs old, stop after screening result (-)
|
• HPV-DNA test can be the primary screening every 5 years
• >30 yrs old with ASC-US can perform HPV-DNA test after 6 months
|
|
India
|
|
Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI)
|
FOGSI
|
• <25 yrs old, no screening
• 25-29 yrs old, cytology alone every 3 yrs
• 30-65 yrs old, HPV testing or co-testing every 5 yrs
• >65 yrs old, stop after screening result (-) and
no history of CIN2+ within the last 20 years
|
• Primary HPV testing
• Co-testing (HPV and cytology)
*In an Indian study, even a single round of HPV testing was shown to reduce the incidence of cervical cancer significantly
|
Latest Guidelines for Cervical Cancer Screening (general population without HIV/ADIS)
Source: Bioperfectus international marketing team database
*Abbreviations
ACOG: American College of Obstetricians and Gynecologists
ASCCP: American Society for Colposcopy and Cervical Pathology
SGO: Society of Gynecologic Oncology
USPSTF: the U.S. Preventive Services Task Force
ABPTGIC: The Brazilian Association for the Lower Genital Tract Pathology and Colposcopy
FOGSI: Federation of Obstetrics and Gynecologic Societies of India
Though all laboratories in each country and region shall develop their algorithms under local guidelines, which are recommended to follow a WHO strategy, a co-test combining the HPV DNA test and the cytologic test is usually put into practice as a screening strategy for cervical screening in clinical settings. As for cytologic tests, specimens preserved in a solution of Hologic ThinPrep® and BD SurePath™ are most commonly used for liquid-based cytologic tests.
Today Bioperfectus is pleased to announce that the Bioperfectus HPV DNA Test Total Solution is officially validated with a specimen collected by BD SurePath™ Collection Vial to better serve the work routine of laboratories in terms of cervical cancer screening.
